Shinichiro Tada

2.1k total citations · 1 hit paper
39 papers, 1.7k citations indexed

About

Shinichiro Tada is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Shinichiro Tada has authored 39 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 18 papers in Epidemiology and 9 papers in Molecular Biology. Recurrent topics in Shinichiro Tada's work include Liver Disease Diagnosis and Treatment (14 papers), Hepatitis C virus research (13 papers) and Hepatitis B Virus Studies (7 papers). Shinichiro Tada is often cited by papers focused on Liver Disease Diagnosis and Treatment (14 papers), Hepatitis C virus research (13 papers) and Hepatitis B Virus Studies (7 papers). Shinichiro Tada collaborates with scholars based in Japan, United States and Israel. Shinichiro Tada's co-authors include Hidetsugu Saito, Tanya Rozovskaia, Carlo M. Croce, Alexander Mazo, Eli Canaani, Tatsuya Nakamura, G C Dubois, Haruka Kusakari, Władysław Krajewski and Eriko Kitamura and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Molecular Cell and Gastroenterology.

In The Last Decade

Shinichiro Tada

38 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ALL-1 Is a Histone Methyltransferase that Assembles a Supercomplex of Proteins Involved in Transcriptional Regulation

2002 567 citations Shinichiro Tada et al. profile →

Peers

Countries citing papers authored by Shinichiro Tada

Since Specialization

Citations

This map shows the geographic impact of Shinichiro Tada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinichiro Tada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinichiro Tada more than expected).

Fields of papers citing papers by Shinichiro Tada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinichiro Tada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinichiro Tada. The network helps show where Shinichiro Tada may publish in the future.

Co-authorship network of co-authors of Shinichiro Tada

This figure shows the co-authorship network connecting the top 25 collaborators of Shinichiro Tada. A scholar is included among the top collaborators of Shinichiro Tada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinichiro Tada. Shinichiro Tada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A case of severe osteomalacia caused by Tubulointerstitial nephritis with Fanconi syndrome in asymptomotic primary biliary cirrhosis 2015 ·BMC Nephrology ·Shintaro Yamaguchi, Tatsuya Maruyama, Shu Wakino, Hirobumi Tokuyama, Akinori Hashiguchi, Shinichiro Tada, Koichiro Homma, Toshiaki Monkawa, James H. Thomas, Kazutoshi Miyashita, Isao Kurihara, Tadashi Yoshida, Konosuke Konishi, Kôichi Hayashi, Matsuhiko Hayashi, Hiroshi Itoh	17
2	Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score 2011 ·Hepatology International ·Hirotoshi Ebinuma, Hidetsugu Saito, Shinichiro Tada, Nobuhiro Nakamoto, (unknown), Satoshi Tsunematsu, Naoki Kumagai, Kanji Tsuchimoto, Nobuhiro Tsukada, Yasutaka Inagaki, Yoshinori Horie, Masahiko Takahashi, Kazuhiro Atsukawa, (unknown), Takanori Kanai∥, Toshifumi Hibi∥	6
3	DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL‐mediated apoptosis via up‐regulation of TRAIL‐R2/DR5 and caspase‐8 2010 ·Cancer Science ·Satoshi Kurita, Hajime Higuchi, Yoshimasa Saito, Nobuhiro Nakamoto, Hiromasa Takaishi, Shinichiro Tada, Hidetsugu Saito, Gregory J. Gores, Toshifumi Hibi	36
4	A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis 2009 ·Journal of Gastroenterology ·Yoshiyuki Yamagishi, Hidetsugu Saito, Hirotoshi Ebinuma, Masahiro Kikuchi, Keisuke Ojiro, (unknown), Shinichiro Tada, Yoshinori Horie, Shinzo Kato, Toshifumi Hibi∥	28
5	Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment 2008 ·Journal of Medical Virology ·Mitsuyasu Nakamura, Hidetsugu Saito, Masanori Ikeda, Shinichiro Tada, Naoki Kumagai, Nobuyuki Kato, Kunitada Shimotohno, Toshifumi Hibi∥	9
6	Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab 2008 ·Journal of Gastroenterology ·Keisuke Ojiro, Makoto Naganuma, Hirotoshi Ebinuma, Hiroyoshi Kunimoto, Shinichiro Tada, Haruhiko Ogata, Yasushi Iwao, Hidetsugu Saito, Toshifumi Hibi∥	72
7	Treatment of hepatitis C virus with peg‐interferon and ribavirin combination therapy significantly affects lipid metabolism 2008 ·Hepatology Research ·Shinichiro Tada, Hidetsugu Saito, Hirotoshi Ebinuma, Keisuke Ojiro, Yoshiyuki Yamagishi, Naoki Kumagai, Yasutaka Inagaki, (unknown), Jiro Nishida, Masahiko Takahashi, Hiroshi Nagata, Toshifumi Hibi∥	34
8	A case of primary amyloidosis developing acute liver failure 2006 ·Kanzo ·Yoshiyuki Yamagishi, (unknown), Michinaga Matsumoto, Atsushi Nakazawa, Satoshi Kurita, Shinichiro Tada, Akinori Hashiguchi, Hiroaki Yokomori, Hidetsugu Saito, Shinzo Kato, Toshifumi Hibi∥	2
9	Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis 2006 ·Journal of Gastroenterology and Hepatology ·(unknown), Shinichiro Tada, Nobuhiro Nakamoto, Kyoko Toda, (unknown), Satoshi Kurita, Satoshi Tsunematsu, Naoki Kumagai, Hiromasa Ishii, (unknown), Toshifumi Hibi∥	40
10	Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C 2006 ·The Keio Journal of Medicine ·Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Hiromasa Ishii, (unknown), Jiro Nishida, Takeshi Yoshida, (unknown), Hideo Yoshida, (unknown), Yasutaka Inagaki, Naoki Kumagai, Toshifumi Hibi∥	5
11	Role of Erythrocytes as a Reservoir for Ribavirin and Relationship with Adverse Reactions in the Early Phase of Interferon Combination Therapy for Chronic Hepatitis C Virus Infections 2006 ·Journal of Clinical Microbiology ·Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Hiromasa Ishii, (unknown), Masahiko Takahashi, Nobuhiro Tsukada, Jiro Nishida, Shin Tanaka, Hiroshi Shiozaki, Toshifumi Hibi∥	18
12	Spontaneous regression of hepatocellular carcinoma in S4 after another tumor in S1 was chemoembolized 2005 ·Kanzo ·Tetsuro Takayama, Shinichiro Tada, (unknown), Hidetsugu Saito, Toshifumi Hibi∥	0
13	Clinical usefulness of edaravone for acute liver injury 2003 ·Journal of Gastroenterology and Hepatology ·Shinichiro Tada, Nobuhiro Nakamoto, Kaori Kameyama, Satoshi Tsunematsu, Naoki Kumagai, Hidetsugu Saito, Hiromasa Ishii	39
14	A Free Radical Scavenger, Edaravone, Attenuates Steatosis and Cell Death via Reducing Inflammatory Cytokine Production in Rat Acute Liver Injury 2003 ·Free Radical Research ·Nobuhiro Nakamoto, Shinichiro Tada, Kaori Kameyama, (unknown), Satoshi Kurita, Yoshimasa Saito, Hidetsugu Saito, Hiromasa Ishii	30
15	The Detection of IRF-1 Promoter Polymorphisms and Their Possible Contribution to T Helper 1 Response in Chronic Hepatitis C 2002 ·Journal of Interferon & Cytokine Research ·Hidetsugu Saito, Shinichiro Tada, Kanji Wakabayashi, Nobuhiro Nakamoto, Masahiko Takahashi, Mitsuyasu Nakamura, Hirotoshi Ebinuma, Hiromasa Ishii	14
16	Interferon regulatory factor 1 promoter polymorphism and response to type 1 interferon 2001 ·Journal of Cellular Biochemistry ·Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Kanji Wakabayashi, (unknown), Yoshimasa Saito, Nobuhiro Nakamoto, Satoshi Kurita, Hiromasa Ishii	17
17	Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c‐H‐ras gene 1997 ·Journal of Gastroenterology and Hepatology ·Satoshi Tsunematsu, Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Masaharu Tsuchiya, Naoki Kumagai, Toshio Morizane, Tatsuji Nomura, Hiromasa Ishii	20
18	Kupffer cell-mediated cytotoxicity against hepatoma cells occurs through production of nitric oxide and adhesion via ICAM-1/CD18 1996 ·International Immunology ·Hidetsugu Saito, Iwao Kurose, Hirotoshi Ebinuma, Dai Fukumura, Hajime Higuchi, Kazuhiro Atsukawa, Shinichiro Tada, Hiroyuki Kimura, Yoshikazu Yonei, (unknown), Soichiro Miura, Hiromasa Ishii	12
19	Keio Multicenter Trial in High-dose Interferon-.ALPHA.2b Treatment for Chronic Hepatitis C. 1996 ·The Keio Journal of Medicine ·Hidetsugu Saito, Kanji Tsuchimoto, Shingo Miyaguchi, Shinichiro Tada, (unknown), (unknown), (unknown), Tetsu Watanabe, Toshio Morizane, Hiromasa Ishii	7
20	Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer 1994 ·Journal of Gastroenterology ·Hidetsugu Saito, Shinichiro Tada, Hirotoshi Ebinuma, Satoshi Tsunematsu, Tatehiro Kagawa, Naoki Kumagai, Yasutaka Inagaki, Tetsu Watanabe, Kanji Tsuchimoto, Toshio Morizane, Hiromasa Ishii, Masaharu Tsuchiya	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact